

Prevymis™ (letermovir)
Effective 07/01/2025

| | | | |
|------------------------------|--|--|---|
| Plan | <input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange | Program Type | <input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy |
| Benefit | <input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit | | |
| Specialty Limitations | This medication has been designated specialty and must be filled at a contracted specialty pharmacy. | | |
| Contact Information | Medical Benefit Pharmacy Benefit | Phone: 833-895-2611 Phone: 800-711-4555 | Fax: 888-656-6671 Fax: 844-403-1029 |
| Exceptions | N/A | | |

Overview

Prevymis (letermovir) is a cytomegalovirus (CMV) DNA terminase complex inhibitor indicated for:

- Prophylaxis of CMV infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
- Prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])

Prevymis is available as tablets and pellets for oral administration and solution for intravenous administration. Prevymis injection should be used only in patients unable to take oral therapy. Patients should be switched to oral Prevymis as soon as they are able to take oral medications.

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted all of the following criteria are met:

Prophylaxis of CMV Infection And Disease in Members who are CMV-Seropositive Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

1. Documentation the member has received an allogeneic hematopoietic stem cell transplant (HSCT) OR is scheduled to receive, a HSCT. - **Date of HSCT must be submitted on the request**
2. Member is at high risk of CMV infection as defined by:
 - a. CMV-seropositive recipients OR
 - b. Seronegative recipients who have received a graft from a seropositive donor.
3. If the request is for the IV formulation, documentation must be submitted with clinical rationale as to why the member cannot take the oral tablets.

Prophylaxis of CMV Disease in Members who are Kidney Transplant Recipients at High Risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])

1. Documentation the member has received a kidney transplant OR is scheduled to receive a kidney transplant – **Date of kidney transplant must be submitted on the request**
2. Member is at high risk of CMV infection (donor CMV seropositive/recipient CMV seronegative [D+/R-])
3. If the request is for the IV formulation, documentation must be submitted with clinical rationale as to why the member cannot take the oral tablets.

Limitations

1. Authorizations will be limited to a maximum of:

| | |
|-------------------|--|
| HSCT Transplant | 100 days post-transplant May continue through 200 days if patient is at risk for late CMV infection and disease (documentation is required) |
| Kidney transplant | 200 days post-transplant |

References

1. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. *N Engl J Med* 2014; 370:1781.
2. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. *N Engl J Med*. 2017; 377(25):2433-44.
3. Prevymis (letermovir) [prescribing information]. Rahway, NJ: Merck Sharp & Dohme Corp; January 2025.
4. Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in *Biol Blood Marrow Transplant*. 2010;16(2):294]. *Biol Blood Marrow Transplant*. 2009;15(10):1143-1238. [PubMed 19747629] 10.1016/j.bbmt.2009.06.019

Review History

06/25/18 – Reviewed

06/19/19 – Approved by P&T

05/20/2020 – Reviewed and Updated May P&T; references updated; dosing updated to included oral and IV formulation; added started and stabilized statement. Effective 8/1/20.

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.

12/11/2024 – Reviewed and updated at December P&T. Added supplemental indication for kidney transplantation. Updated approval length to 200 days post-transplant for members at increased risk following HSCT transplant as well as for kidney transplant recipients. Removed age restrictions. Effective 03/01/2025.

04/09/2025 – Reviewed and updated at April P&T. Added Prevymis oral pellet to the policy. Effective 07/01/2025.

